Decreased expression of lysophosphatidylcholine (16:0/OH) in high resolution imaging mass spectrometry independently predicts biochemical recurrence after surgical treatment for prostate cancer

Goto, Takayuki; Terada, Naoki; Inoue, Takahiro; Kobayashi, Takashi; Nakayama, Kenji; Okada, Yoshiyuki; Yoshikawa, Takeshi; Miyazaki, Yu; Uegaki, Masayuki; Utsunomiya, Noriaki; Makino, Yuki; Saito, Shinji; Yamasaki, Toshinari; Kamba, Tomomi; Ogawa, Osamu

doi:10.1002/pros.23088

Cited by 57 publications

(53 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Results showed five lipid species significantly lower in cancer than in benign tissues, specifically: LPC 16:0/OH + H + , LPC 16:0/OH + Na + , LPC 16:0/OH + K + , LPC 16:0/OH + matrix + H + , and SM d18:1/16:0 + H + . A low level of LPC 16:0/OH in cancer tissue was associated with biochemical recurrence after radical prostatectomy [69]. Using ESI-MS/MS lipid profiling, Patel et al analyzed distribution and concentrations of serum PLs from newly diagnosed prostate cancer patients and healthy subjects.…”

Section: Lipidomics In Cancer Researchmentioning

confidence: 99%

“…For example, phosphatidyloserines (PSs) were found differentially expressed in urines of both breast [53] and prostate [64] cancer patients. Serum triacylglycerols (TGs) and linolenic acid seem to have predictive value of therapy response in cases of breast cancer patients receiving neoadjuvant chemotherapy [61,62], whereas plasma levels of different LPCs in colorectal cancer [72] or in prostate cancer [69] were also described. These studies provide a cancer lipid fingerprint in different accessible biofluids, thereby opening the way for the discovery of diagnostic biomarkers able to properly classify cancer patients.…”

Section: Lipidomic Highlights In Cancer Researchmentioning

confidence: 99%

See 1 more Smart Citation

Advances in Lipidomics for Cancer Biomarkers Discovery

Perrotti

Rosa

Cicalini

et al. 2016

IJMS

155

119

View full text Add to dashboard Cite

Lipids play critical functions in cellular survival, proliferation, interaction and death, since they are involved in chemical-energy storage, cellular signaling, cell membranes, and cell–cell interactions. These cellular processes are strongly related to carcinogenesis pathways, particularly to transformation, progression, and metastasis, suggesting the bioactive lipids are mediators of a number of oncogenic processes. The current review gives a synopsis of a lipidomic approach in tumor characterization; we provide an overview on potential lipid biomarkers in the oncology field and on the principal lipidomic methodologies applied. The novel lipidomic biomarkers are reviewed in an effort to underline their role in diagnosis, in prognostic characterization and in prediction of therapeutic outcomes. A lipidomic investigation through mass spectrometry highlights new insights on molecular mechanisms underlying cancer disease. This new understanding will promote clinical applications in drug discovery and personalized therapy.

show abstract

Section: Lipidomics In Cancer Researchmentioning

confidence: 99%

Section: Lipidomic Highlights In Cancer Researchmentioning

confidence: 99%

Advances in Lipidomics for Cancer Biomarkers Discovery

Perrotti

Rosa

Cicalini

et al. 2016

IJMS

155

119

View full text Add to dashboard Cite

show abstract

“…Zeng et al () reported the gene expression profiles regulated by LPA in CaP patients ( n = 10) and benign hyperplasia ( n = 7), where LPA1 mRNA levels were significantly decreased and the LPA3 mRNA level was elevated in cancer epithelia when compared to the benign glands. Goto et al () analyzed tissue samples from CaP patients ( n = 31) and controls with positive‐ion HR‐MALDI‐IMS to investigate lipid profiles. PL species, [LPC(16:0/OH) + H] + at m/z 496, [LPC(16:0/OH) + Na] + at m/z 518, [LPC(16:0/OH) + K] + at m/z 534, [LPC(16:0/OH) + matrix] + at m/z 690, and SM(d18:1/16:0) + H] + at m/z 703 were significantly decreased in cancer‐tissues compared with normal tissues.…”

Section: Ms‐based Analysis Of Pls In Various Cancers and Biomarker DImentioning

confidence: 99%

Phospholipids as cancer biomarkers: Mass spectrometry‐based analysis

Bandu

Mok

Kim

2016

Mass Spectrometry Reviews

139

114

View full text Add to dashboard Cite

Lipids, particularly phospholipids (PLs), are key components of cellular membrane. PLs play important and diverse roles in cells such as chemical-energy storage, cellular signaling, cell membranes, and cell-cell interactions in tissues. All these cellular processes are pertinent to cells that undergo transformation, cancer progression, and metastasis. Thus, there is a strong possibility that some classes of PLs are expected to present in cancer cells and tissues in cellular physiology. The mass spectrometric soft-ionization techniques, electrospray ionization (ESI), and matrix-assisted laser desorption/ionization (MALDI) are well-established in the proteomics field, have been used for lipidomic analysis in cancer research. This review focused on the applications of mass spectrometry (MS) mainly on ESI-MS and MALDI-MS in the structural characterization, molecular composition and key roles of various PLs present in cancer cells, tissues, blood, and urine, and on their importance for cancer-related problems as well as challenges for development of novel PL-based biomarkers. The profiling of PLs helps to rationalize their functions in biological systems, and will also provide diagnostic information to elucidate mechanisms behind the control of cancer, diabetes, and neurodegenerative diseases. The investigation of cellular PLs with MS methods suggests new insights on various cancer diseases and clinical applications in the drug discovery and development of biomarkers for various PL-related different cancer diseases. PL profiling in tissues, cells and body fluids also reflect the general condition of the whole organism and can indicate the existence of cancer and other diseases. PL profiling with MS opens new prospects to assess alterations of PLs in cancer, screening specific biomarkers and provide a basis for the development of novel therapeutic strategies. © 2016 Wiley Periodicals, Inc. Mass Spec Rev 37:107-138, 2018.

show abstract

“…52 We have examined the lipid expression profiles of prostate cancer tissues using high-resolution imaging mass spectrometry 53 and found that decreased expression of lysophosphatidylcholine independently predicts biochemical recurrence. 54 We have also found, using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry, that a C-terminal PSA fragment composed of 19 amino acid residues is a potential novel urine biomarker for diagnosis of prostate cancer. 55 However, it was difficult to establish the method to measure the concentration of these lipids or proteins.…”

Section: Circulating Tumor Cells and Cell-free Dna As Novel Liquid Bimentioning

confidence: 88%

Prognostic and predictive biomarkers in prostate cancer: latest evidence and clinical implications

et al. 2017

Self Cite

View full text Add to dashboard Cite

Advances in our understanding of the mechanisms driving castration-resistant prostate cancer have promoted the development of several new drugs including androgen receptor-directed therapy and chemotherapy. Concomitant docetaxel treatment at the beginning of hormonal therapy for metastatic prostate cancer has resulted in longer overall survival than with hormonal therapy alone. Elucidating an appropriate treatment sequence using these therapies is important for maximizing clinical benefit in castration-sensitive and castration-resistant prostate cancer patients. The development of advanced high-throughput ‘omics’ technology has enabled the use of novel markers to guide prognosis and treatment of this disease. In this review, we outline the genomic landscape of prostate cancer and the molecular mechanisms of castration-resistant progression, and how these affect the development of new drugs, and their clinical implications for selecting treatment sequence. We also discuss many of the potential tissue-based or liquid biomarkers that may soon enter clinical use, with the hope that several of these prognostic or predictive markers will guide precision medicine for prostate cancer patients in the near future.

show abstract

Decreased expression of lysophosphatidylcholine (16:0/OH) in high resolution imaging mass spectrometry independently predicts biochemical recurrence after surgical treatment for prostate cancer

Cited by 57 publications

References 49 publications

Advances in Lipidomics for Cancer Biomarkers Discovery

Advances in Lipidomics for Cancer Biomarkers Discovery

Phospholipids as cancer biomarkers: Mass spectrometry‐based analysis

Prognostic and predictive biomarkers in prostate cancer: latest evidence and clinical implications

Contact Info

Product

Resources

About